Menu
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€68.46

€68.46

0.350%
0.24
0.350%
-
 
16:21 / Tradegate WKN: A2PDXE / Name: Alcon / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...
Your prediction

Alcon AG Stock

The Alcon AG stock is trending slightly upwards today, with an increase of €0.24 (0.350%) compared to yesterday's price.

Pros and Cons of Alcon AG in the next few years

Pros
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval: https://mms.businesswire.com/media/20250708893871/en/2517069/5/AC7695_Unityvcs-product-visuals_1by1-blue_07-07-2025_RM.jpg
Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval


Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)


Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for

Alcon Canada Earns Global Recognition as a Top Employer
Alcon Canada Earns Global Recognition as a Top Employer


Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a